XNAS
NNOX
Market cap83mUSD
Jul 09, Last price
1.17USD
1D
-3.31%
1Q
-48.46%
IPO
-95.62%
Name
Nano-X Imaging Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nano-X Imaging Ltd. specializes in developing a commercial-grade tomographic imaging device that incorporates an innovative digital X-ray source, which leverages a digital micro-electro-mechanical systems (MEMS) semiconductor cathode. Beyond its hardware focus, the company also delivers teleradiology services and creates artificial intelligence (AI) applications tailored for practical use in medical imaging. Its core offerings include the Nanox.ARC, a prototype medical imaging system that integrates its proprietary digital X-ray technology, and Nanox.CLOUD, a complementary cloud-based software platform envisioned to facilitate medical screening as a service. Nano-X also operates Nanox.MARKETPLACE, a platform designed to connect imaging facilities and customers with radiologists for efficient remote interpretation of medical scans. Additionally, the company provides AI-driven software solutions to a wide range of healthcare entities, including hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers. These solutions are designed to analyze data from existing computed tomography (CT) scans to identify or predict undiagnosed or underdiagnosed medical conditions, such as osteoporosis and cardiovascular disease. Nano-X further offers Teleradiology Services, delivering remote imaging interpretation to radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities, and multi-specialty physician groups. Founded in 2011, Nano-X Imaging Ltd. is headquartered in Neve Ilan, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||